Last week in London, Dr. Gruber delivered the keynote presentation at the 2nd International Congress on Clinical Trials on Cannabis (CT-Cann2023). The presentation included findings from our open-label clinical trial of a full-spectrum, high-CBD product for anxiety as well as our observational, longitudinal studies. Read some of the key insights from recent press coverage here.
Comments